Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sensus Healthcare (SRTS) Gains from Sales and Divestitures (2017 - 2025)

Sensus Healthcare has reported Gains from Sales and Divestitures over the past 9 years, most recently at $50000.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 31.03% year-over-year to $50000.0; the TTM value through Dec 2025 reached $50000.0, down 31.03%, while the annual FY2025 figure was $50000.0, 31.03% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $50000.0 at Sensus Healthcare, up from $10000.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $72500.0 in Q4 2024 and troughed at $8750.0 in Q2 2021.
  • A 5-year average of $29578.9 and a median of $15000.0 in 2023 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 86.88% in 2021 and later soared 71.43% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $43750.0 in 2021, then decreased by 5.71% to $41250.0 in 2022, then surged by 59.39% to $65750.0 in 2023, then grew by 10.27% to $72500.0 in 2024, then tumbled by 31.03% to $50000.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for SRTS at $50000.0 in Q4 2025, $10000.0 in Q3 2025, and $10000.0 in Q2 2025.